ANNAPOLIS, Md., Nov. 6 PharmAthene, Inc.(NYSE: PIP) a biodefense company developing medical countermeasures againstbiological and chemical threats, announced today that its financial resultsfor the third quarter of 2008 will be released on Thursday, November 13, 2008.
PharmAthene management will be hosting a conference call to discuss itsthird quarter 2008 financial results. The call is scheduled to begin at 4:30p.m. Eastern Time on Thursday, November 13, 2008 and will last approximately45 minutes.
The dial-in number for U.S. callers is 800-798-2801 and for internationalcallers is 617-614-6205. The participant passcode is 81927054.
A replay of the conference call will be available for 30 days, beginningat approximately 6:30 p.m. E.T. on November 13, 2008 until approximately 11:50p.m. E.T. December 13, 2008. The dial-in number for U.S. callers is888-286-8010, and for international callers is 617-801-6888. The participantpasscode is 74215682.
The webcast of the conference call can be accessed from the company'swebsite at http://www.pharmathene.com . A link to the webcast may be found onthe Investor Relations section of the website.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States andits allies by developing and commercializing medical countermeasures againstbiological and chemical weapons. PharmAthene's lead product developmentprograms include:-- SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine -- Third generation rPA anthrax vaccine -- Valortim(R) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection -- Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents -- RypVax(TM) -- a recombinant dual antigen vaccine for plague For more information about PharmAthene, please visit www.PharmAthene.com . Contact: Stacey Jurchison PharmAthene, Inc. Phone: 410-269-2610 JurchisonS@PharmAthene.com
SOURCE PharmAthene, Inc.